Trial Profile

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JAB-2485 (Primary)
Indications Advanced breast cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Jacobio Pharmaceuticals

17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress.
30 Aug 2023 According to Jacobio media release, efficacy signals have been observed in the first dose group.
22 Mar 2023 According to Jacobio media release, in China, the RP2D application for a Phase I/IIa trial was approved by the CDE in October 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com